Literature DB >> 26628266

ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis.

Animesh D Pardanani1, Terra L Lasho2, Christy Finke2, Darci L Zblewski2, Ramy A Abdelrahman2, Emnet A Wassie2, Naseema Gangat2, Curtis A Hanson3, Rhett P Ketterling4, Ayalew Tefferi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26628266     DOI： 10.1111/bjh.13865

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  11 in total

Review 1.  The new tool "KIT" in advanced systemic mastocytosis.

Authors:  William Shomali; Jason Gotlib
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Authors:  Animesh Pardanani; Sahrish Shah; Francesco Mannelli; Yoseph C Elala; Paola Guglielmelli; Terra L Lasho; Mrinal M Patnaik; Naseema Gangat; Rhett P Ketterling; Kaaren K Reichard; Curtis A Hanson; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Blood Adv       Date:  2018-11-13

3.  Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis.

Authors:  A Tefferi; T L Lasho; C Finke; N Gangat; C A Hanson; R P Ketterling; A Pardanani
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

4.  Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.

Authors:  Preetesh Jain; Sa Wang; Keyur P Patel; Nawid Sarwari; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-06-01       Impact factor: 3.156

Review 5.  The international consensus classification of mastocytosis and related entities.

Authors:  Roos J Leguit; Sa A Wang; Tracy I George; Alexandar Tzankov; Attilio Orazi
Journal:  Virchows Arch       Date:  2022-10-10       Impact factor: 4.535

Review 6.  Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.

Authors:  Oscar González-López; Javier I Muñoz-González; Alberto Orfao; Iván Álvarez-Twose; Andrés C García-Montero
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

7.  The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.

Authors:  Mohamad Jawhar; Juliana Schwaab; Manja Meggendorfer; Nicole Naumann; Hans-Peter Horny; Karl Sotlar; Torsten Haferlach; Karla Schmitt; Alice Fabarius; Peter Valent; Wolf-Karsten Hofmann; Nicholas C P Cross; Georgia Metzgeroth; Andreas Reiter
Journal:  Haematologica       Date:  2017-03-02       Impact factor: 9.941

8.  Validation of the Mayo alliance prognostic system for mastocytosis.

Authors:  Francesco Mannelli; Francesca Gesullo; Giada Rotunno; Annalisa Pacilli; Lisa Pieri; Paola Guglielmelli; Alessandro M Vannucchi
Journal:  Blood Cancer J       Date:  2019-02-11       Impact factor: 11.037

Review 9.  Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.

Authors:  Cecilia Monaldi; Sara De Santis; Manuela Mancini; Samantha Bruno; Michele Cavo; Simona Soverini
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-07-01       Impact factor: 2.576

Review 10.  Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis.

Authors:  Francesco Mannelli
Journal:  Ann Hematol       Date:  2020-11-06       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.